Skip to main content
Clinical Trials/NCT05524402
NCT05524402
Completed
N/A

Live Video Mind-body Treatment to Prevent Persistent Symptoms Following mTBI

Massachusetts General Hospital1 site in 1 country50 target enrollmentOctober 15, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
MTBI - Mild Traumatic Brain Injury
Sponsor
Massachusetts General Hospital
Enrollment
50
Locations
1
Primary Endpoint
Number of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire (CEQ)
Status
Completed
Last Updated
last year

Overview

Brief Summary

The investigator aims to conduct a pilot randomized controlled trial to test the feasibility of two symptom management programs for college-age individuals with recent concussions and anxiety, TOR-C 1 and TOR-C 2. The investigator will assess the feasibility of recruitment procedures (screening, eligibility, and enrollment) and data collection as well as the feasibility, credibility, and acceptability of the programs (adherence, retention, fidelity, and satisfaction), following prespecified benchmarks. Both programs will be delivered virtually (Zoom).

Detailed Description

The investigator aims to conduct a pilot randomized controlled trial to test the feasibility of two symptom management programs for college-age individuals with recent concussions and anxiety, TOR-C 1 and TOR-C 2. The investigator will assess the feasibility of recruitment procedures (screening, eligibility, and enrollment) and data collection as well as the feasibility, credibility, and acceptability of the programs (adherence, retention, fidelity, and satisfaction), following prespecified benchmarks. Both programs will be delivered virtually (Zoom). Each program will consist of four 45-minute sessions over the secure Zoom platform. Participants will receive a treatment manual. There are 3 assessment points consisting of self-report surveys: baseline, post program, and 3-month follow-up.

Registry
clinicaltrials.gov
Start Date
October 15, 2022
End Date
July 12, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jonathan Greenberg

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Male and female outpatients, ages 18-35
  • English fluency and literacy
  • Diagnosed with a concussion in the past 10 weeks
  • Owns a smartphone or computer with Internet access
  • Willingness and ability to participate in four 45-minute program sessions and answer remote questionnaires before, after, and 3-month following the program
  • Free of concurrent psychotropic or have been on stable dosage for at least 6 weeks
  • Clinically significant anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)

Exclusion Criteria

  • Previous history of moderate or severe TBI OR concussion in the past 2 years that resulted in symptoms lasting 3 months or more
  • Diagnosed with a medical illness expected to worsen in the next 6 months (e.g., malignancy)
  • Lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder
  • Current substance abuse or dependence and current substance use disorder
  • Current active self-reported suicidal ideation
  • Practice of mindfulness techniques for greater than 45 minutes per week within the last 3 months
  • Participation in a mind-body or CBT treatment in the past 3 months
  • Currently pregnant

Outcomes

Primary Outcomes

Number of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire (CEQ)

Time Frame: Baseline (0 Weeks)

Assessed using the Credibility and Expectancy Questionnaire (CEQ) which asks the participant indicate how much they believe, right now, that the intervention they will receive will help manage their concussion and related worry. Possible scores on both the credibility and expectancy subscales range from 3 to 27 and have a midpoint score of 14. The number of participants that scored at or above 14 on the credibility and/or expectancy subscales are reported below.

Number of Participants Who Scored Above the Midpoint on the Client Satisfaction Scale

Time Frame: Post-Test (4 Weeks)

Measured using the Client Satisfaction Scale which assess participants' satisfaction with participation in the study. The score range is 0-12. Higher scores indicate greater satisfaction.

Feasibility of Recruitment

Time Frame: Baseline (0 Weeks)

Rate at which recruitment was possible

Acceptability of Treatment

Time Frame: Post-Test (4 Weeks)

Rate at which program was accepted, measured by attendance.

Adherence to Homework

Time Frame: Collected during intervention, an average of 4 weeks

Rate of participant's completion of homework assigned (practicing at least 1 program skill, 3 days/week on average) throughout the study.

Therapist Adherence

Time Frame: Collected during intervention, an average of 4 weeks

Rate of interventionist's delivering the programs by following the established session topics and practices

Feasibility of Assessments at Baseline

Time Frame: Baseline (0 Weeks)

Rate of participant's completion of self-report measures, with no measures missing

Feasibility of Assessments at Post-Test

Time Frame: Post-Test (4 Weeks)

Rate of participant's completion of self-report measures, with no measures missing

Feasibility of Assessments at Follow-up

Time Frame: Follow-up (12 Weeks)

Rate of participant's completion of self-report measures, with no measures missing

Adverse Events

Time Frame: Collected during intervention, an average of 4 weeks

Any self reported or observed negative events related to participation

Secondary Outcomes

  • Numerical Rating Scale(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Post-Concussion Symptom Scale (PCSS)(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Generalized Anxiety Disorder Scale (GAD-7)(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Hospital Anxiety And Depression Scale (HADS)(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • World Health Organization - Disability Assessment Schedule 2.0 (WHODAS)(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Fear Avoidance Behavior After Traumatic Brain Injury (FAB-TBI)(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Pain Catastophizing Scale (PCS)(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Cognitive And Affective Mindfulness Scale-Revised (CAMS-R)(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Behavioral Response To Illness (BRIQ) - Limiting Behaviors Subscale(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))
  • Behavioral Response To Illness (BRIQ) - All-or-Nothing Subscale(Baseline (0 Weeks), Post-Test (4 Weeks), Follow-Up (12 Weeks))

Study Sites (1)

Loading locations...

Similar Trials